DISEASE INDICATIONS: Psoriasis
MANUFACTURER: Janssen Biotech
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA)
Therapeutic Goods Administration (TGA)
Tremfya is a pharmaceutical medication that contains the active ingredient guselkumab. It belongs to a class of medications known as interleukin-23 (IL-23) inhibitors and is primarily used in the treatment of certain chronic skin conditions, particularly moderate to severe plaque psoriasis. Guselkumab works by targeting specific proteins in the immune system that play a role in the development of psoriatic skin lesions, thereby reducing the symptoms associated with this condition.
